Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study

Ling Xu,Wenxiu Peng,Xiaojing Song,Yanling Li,Yang Han,Ting Zhu,Qiang Fu,Xiaoli Du,Wei Cao,Taisheng Li

DOI: https://doi.org/10.1186/s12879-021-05880-8

IF: 3.7

2021-02-17

BMC Infectious Diseases

Abstract:An amendment to this paper has been published and can be accessed via the original article.

infectious diseases

What problem does this paper attempt to address?

Erratum to “The Feasibility of Xpert MTB/RIF Testing to Detect Rifampicin Resistance among Childhood Tuberculosis for Prevalence Surveys in Northern China”

Jie Lu,Huimin Li,Fang Dong,Jin Shi,Hui Yang,Shujing Han,Ping Chu,Yanlin Zhao,Wenqi Song,Yongli Guo,Shunying Zhao

DOI: https://doi.org/10.1155/2018/4360219

2018-09-06

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2017/5857369.].

biotechnology & applied microbiology,medicine, research & experimental
Corrigendum to “sex Differences in HIV Treatment Outcomes and Adherence by Exposure Groups among Adults in Guangdong, China: A Retrospective Observational Cohort Study” [eclinicalmedicine 22 (2020) 100351]

Linghua Li,Tanwei Yuan,Junfeng Wang,Thomas Fitzpatrick,Quanmin Li,Peiyang Li,Xiaoping Tang,Guohong Xu,Dahui Chen,Bowen Liang,Weiping Cai,Huachun Zou

DOI: https://doi.org/10.1016/j.eclinm.2020.100618

IF: 15.1

2020-01-01

EClinicalMedicine

Abstract:[This corrects the article DOI: 10.1016/j.eclinm.2020.100351.].
Correction: Corrigendum: Increased Duodenal Eosinophil Degranulation in Patients with Functional Dyspepsia: A Prospective Study

Lijun Du,Jinhua Shen,John J. Kim,Yunxian Yu,Lu Ma,Ning Dai

DOI: https://doi.org/10.1038/srep46121

IF: 4.6

2017-01-01

Scientific Reports

Abstract:Scientific Reports 6: Article number: 34305; published online: 06 October 2016; updated: 07 April 2017 Affiliation 1 was incorrectly listed as ‘Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang province 310016, China’ in the original version of the Article.
Corrigendum to "trend of HIV-1 Drug Resistance in China: A Systematic Review and Meta-Analysis of Data Accumulated over 17 Years (2001-2017)" [eclinicalmedicine 18 (2020) 100238].

Lulu Zuo,Kai Liu,Honglian Liu,Yihong Hu,Zhijie Zhang,Jianru Qin,Qinggang Xu,Ke Peng,Xia Jin,Jian-Hua Wang,Chiyu Zhang

DOI: https://doi.org/10.1016/j.eclinm.2020.100696

IF: 15.1

2021-01-01

EClinicalMedicine

Abstract:[This corrects the article DOI: 10.1016/j.eclinm.2019.100238.].
Author Correction: BHMT Polymorphism and Susceptibility to PTE in Chinese Patients.

W-H Zhang,S-M Zhao,J-F Guo,Y-P Liu,Y-Q Jiang

DOI: https://doi.org/10.26355/eurrev_202307_32944

2023-01-01

European review for medical and pharmacological sciences

Abstract:Correction to: Eur Rev Med Pharmacol Sci 2023; 27 (9): 4098-4102. DOI: 10.26355/eurrev_202305_32317-PMID: 37203835-published online on May 15, 2023. After publication, the authors applied a correction in the Funding section. The section has been amended as follows: This study was supported by the research program of Jilin Provincial Science and Technology Department (No. 20190201011J). There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/32317.
Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Hang-Ping Yao,Liang Feng,Sreedhar Reddy Suthe,Ling-Hui Chen,Tian-Hao Weng,Chen-Yu Hu,Eun Sung Jun,Zhi-Gang Wu,Wei-Lin Wang,Song Cheol Kim,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1186/s40425-019-0571-7

IF: 12.469

2019-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Following publication of the original article [1], the author reported two errors in the authors affiliations:
Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study

Jing Xiao,Jiang Xiao,Ying Liu,Bei Li,Leidan Zhang,Junyan Han,Hongxin Zhao

DOI: https://doi.org/10.1016/j.ijid.2022.01.051

Abstract:Background: Efavirenz (EFV) 400 mg has been recommended to replace EFV 600 mg. There are only 200 mg and 600 mg dosage forms of EFV in China. Whether switching from one-tablet EFV 600 mg to two-tablet EFV 200 mg would weaken adherence or further affect efficacy or safety is unknown. Methods: Virologically suppressed people living with HIV with a regimen composed of one-tablet tenofovir (TDF), one-tablet lamivudine (3TC), and one-tablet EFV (600 mg) were randomized to continue original regimen or switch to two-tablet EFV (200 mg). Self-reported adherence questionnaires, 12-Item Short-Form Health Survey (SF-12), Hospital Anxiety and Depression Scale (HADS), and Pittsburgh Sleep Quality Index (PSQI) were used. Primary end point was the difference in proportions of participants with plasma HIV-RNA ≥ 50 copies/mL at week 48 with noninferiority margin of 4%. Results: A total of 209 participants were randomized to the EFV 400 mg group and 211 to the EFV 600 mg. Primary end point result was -3.3% (95% CI -8.1-1.6). Further decrease of GGT (-3.1 vs. -0.3 U/L) and TC (-0.26 vs. 0.12 U/L) was observed in EFV 400 mg participants through 48 weeks. No significant changes in adherence, quality of life, and neuropsychologic condition were reported. Conclusions: EFV 400 mg was noninferior to EFV 600 mg and showed mild improvement of safety profile. Adherence was not weakened in patients taking EFV 400 mg. For patients taking EFV 600 mg with neuropsychologic symptoms, it would be better to switch to other drugs instead of EFV 400 mg.
Corrigendum to “effects of a Symptom Management Intervention Based on Group Sessions Combined with a Mobile Health Application for Persons Living with HIV in China: A Randomized Controlled Trial” [int J Nurs Sci 8 (2021) 370–379]

Shuyu Han,Yaolin Pei,Rui Zhao,Yan Hu,Lin Zhang,Xiang Qi,Zheng Zhu,Wenxiu Sun,Bei Wu

DOI: https://doi.org/10.1016/j.ijnss.2023.09.023

2023-01-01

International Journal of Nursing Sciences

Abstract:[This corrects the article DOI: 10.1016/j.ijnss.2021.07.002.].
Pharmacogenomics and Pharmacokinetics of Efavirenz 400 or 600 Mg in 184 Treatment-Naive HIV-infected Patients in China

Rong Chen,Jun Chen,Jingna Xun,Zhiliang Hu,Qiong Huang,Renfang Zhang,Corky Steinhart,Yinzhong Shen,Li Liu,Hongzhou Lu

DOI: https://doi.org/10.2217/pgs-2019-0169

2020-01-01

Pharmacogenomics

Abstract:Background: The pharmacogenomics and pharmacokinetics/pharmacodynamics of 400 mg efavirenz have rarely been reported. Materials & methods: A total of 184 treatment-naive HIV-infected patients were randomly assigned (1:1) to receive a lower dose (tenofovir disoproxil 200 mg, efavirenz 400 mg and lamivudine) or a standard dose regimen. Relationships between pharmacogenomics and efavirenz pharmacokinetics/pharmacodynamics were explored at 48 weeks. Results: There was no relationship between pharmacogenomics and adverse reactions of the central nervous system and antiretoviral efficacy. CYP2B6 516G>T, 785A>G, 18492C>T and ABCB1 3435C>T T/C were associated with higher efavirenz plasma levels in the standard but not the lower dose group. No relationship was found between pharmacogenomics and antiretoviral efficacy. Patients who were <60 kg had higher efavirenz concentration compared with those with weight ≥60 kg when using 600 mg efavirenz, this was not observed with 400 mg efavirenz. Conclusion: The effect of pharmacogenomics and body weight on the efavirenz concentration was significant in the 600 mg group but not in the 400 mg group.
Corrigendum to “artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis”

Lanlan Xiao,Xingqi Xu,Kaizhou Huang,Yalei Zhao,Lingjian Zhang,Lanjuan Li

DOI: https://doi.org/10.1155/2021/9875940

2021-01-01

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2019/3757149.].
Correction To: Safety and Efficacy of Lamivudine or Telbivudine Started in Early Pregnancy for Mothers with Active Chronic Hepatitis B

Tianyu He,Yan Bai,Haodong Cai,Xiaojuan Ou,Liu M,Wei Yi,Jidong Jia

DOI: https://doi.org/10.1007/s12072-018-9876-8

IF: 9.029

2018-01-01

Hepatology International

Abstract:The aim of this erratum is to clearly state the individual author's contribution which was erroneously mentioned as "Tianyu He, Yuqing Bai, Wei Yi, and Jidong Jia contributed equally to this work."
Corrigendum: Investigating the relationship between hepatitis B virus infection and postpartum depression in Chinese women: a retrospective cohort study

Wei Huang,Xiaoli Wu,Zhenzhen Yao,Yingping Gu,Xin Lai,Liping Meng,Songxu Peng

DOI: https://doi.org/10.3389/fpubh.2023.1358590

IF: 5.2

2024-01-08

Frontiers in Public Health

Abstract:[This corrects the article DOI: 10.3389/fpubh.2023.1214151.].

public, environmental & occupational health
Corrigendum: Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora.

Jianfei Long,Jingru Gong,Han Zhu,Xiaolin Liu,Ling Li,Bicui Chen,Hongyan Ren,Chao Liu,Huiping Lu,Jiming Zhang,Bin Wang

DOI: https://doi.org/10.3389/fmicb.2023.1322004

IF: 5.2

2023-01-01

Frontiers in Microbiology

Abstract:[This corrects the article DOI: 10.3389/fmicb.2023.1232180.].
Corrigendum: Digitizing tuberculosis treatment monitoring in Wuhan city, China, 2020–2021: Impact on medication adherence

Mengxian Zhang,Guiyang Wang,Hina Najmi,Aashifa Yaqoob,Tao Li,Yinyin Xia,Jianjun Ye,Shuangyi Hou,Ye Xiao,Liping Zhou,Yuehua Li

DOI: https://doi.org/10.3389/fpubh.2023.1191444

IF: 5.2

2023-04-04

Frontiers in Public Health

Abstract:[This corrects the article DOI: 10.3389/fpubh.2023.1033532.].

public, environmental & occupational health
Erratum for Yang et al., "A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects"

Haijing Yang,Yi Jin,Hailin Wang,Hong Yuan,Jingjing Wang,Size Li,Yingying Hu,Huahui Yang,Xin Li,Hong Liang,Jufang Wu,Guoying Cao,Jing Zhang

DOI: https://doi.org/10.1128/aac.00506-24

IF: 5.938

2024-09-13

Antimicrobial Agents and Chemotherapy

Abstract:Antimicrobial Agents and Chemotherapy, Ahead of Print.

pharmacology & pharmacy,microbiology
Correction To: A Selective Review of Negative Control Methods in Epidemiology

Xu Shi,Miao Wang,Tchetgen

DOI: https://doi.org/10.1007/s40471-021-00270-9

2021-01-01

Current Epidemiology Reports

Abstract:A Correction to this paper has been published: https://doi.org/10.1007/s40471-021-00270-9
Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Bi-Cheng Wang,Bo-Ya Xiao,Peng-Cheng Li,Bo-Hua Kuang,Wang-Bing Chen,Pin-Dong Li,Guo-He Lin,Quentin Liu

DOI: https://doi.org/10.1155/2021/3735726

IF: 4.501

2021-02-25

Journal of Oncology

Abstract:[This corrects the article DOI: 10.1155/2020/2368164.].

oncology
Corrigendum to “efficacy and Safety of Aripiprazole in Chinese Han Schizophrenia Subjects: A Randomized, Double-Blind, Active Parallel-Controlled, Multicenter Clinical Trial” [schizophr. Res. 157 (1–3) (august 2014) 112–119]

Huafang Li,Jianfeng Luo,ChuanyueWang,Shiping Xie,Xiufeng Xu,XiaopingWang,Wenjuan Yu,Niufan Gu,John M. Kane

DOI: https://doi.org/10.1016/j.schres.2014.07.035

IF: 4.662

2014-01-01

Schizophrenia Research

Abstract:a Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Disorders, Shanghai 200030, China b Department of Health Statistics and Social Medicine, School of Public Health, Fudan University, Shanghai 200032, China c Beijing Anding Hospital, Beijing 100088, China d Nanjing Brain Hospital, Nanjing 210029, China e First Affiliated Hospital of Kunming Medical University, Kunming 650032, China f Renmin Hospital of Wuhan University, Wuhan 430060, China g Zucker Hillside Hospital, The Hofstra North Shore-LIJ School of Medicine, Glen Oaks, NY 11004-1100, USA
Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study

Tang-Hsiu Huang,Chin-Wei Kuo,Chian-Wei Chen,Yau-Lin Tseng,Chao-Liang Wu,Sheng-Hsiang Lin

DOI: https://doi.org/10.1186/s12890-021-01559-7

IF: 3.1

2021-06-08

BMC Pulmonary Medicine

Abstract:An amendment to this paper has been published and can be accessed via the original article.

respiratory system
Corrigendum: Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review

Zhi-Hua Yang,Bin Wang,Qian Ma,Lin Wang,Ya-Xin Lin,Hai-Feng Yan,Zi-Xuan Fan,Hao-Jia Chen,Zhao Ge,Feng Zhu,Hui-Jie Wang,Bao-Nan Zhang,Hai-Dong Sun,Li-Min Feng

DOI: https://doi.org/10.3389/fphar.2021.770125

IF: 5.6

2021-10-25

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2021.668407.].

pharmacology & pharmacy

Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study

Erratum to “The Feasibility of Xpert MTB/RIF Testing to Detect Rifampicin Resistance among Childhood Tuberculosis for Prevalence Surveys in Northern China”

Corrigendum to “sex Differences in HIV Treatment Outcomes and Adherence by Exposure Groups among Adults in Guangdong, China: A Retrospective Observational Cohort Study” [eclinicalmedicine 22 (2020) 100351]

Correction: Corrigendum: Increased Duodenal Eosinophil Degranulation in Patients with Functional Dyspepsia: A Prospective Study

Corrigendum to "trend of HIV-1 Drug Resistance in China: A Systematic Review and Meta-Analysis of Data Accumulated over 17 Years (2001-2017)" [eclinicalmedicine 18 (2020) 100238].

Author Correction: BHMT Polymorphism and Susceptibility to PTE in Chinese Patients.

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study

Corrigendum to “effects of a Symptom Management Intervention Based on Group Sessions Combined with a Mobile Health Application for Persons Living with HIV in China: A Randomized Controlled Trial” [int J Nurs Sci 8 (2021) 370–379]

Pharmacogenomics and Pharmacokinetics of Efavirenz 400 or 600 Mg in 184 Treatment-Naive HIV-infected Patients in China

Corrigendum to “artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis”

Correction To: Safety and Efficacy of Lamivudine or Telbivudine Started in Early Pregnancy for Mothers with Active Chronic Hepatitis B

Corrigendum: Investigating the relationship between hepatitis B virus infection and postpartum depression in Chinese women: a retrospective cohort study

Corrigendum: Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora.

Corrigendum: Digitizing tuberculosis treatment monitoring in Wuhan city, China, 2020–2021: Impact on medication adherence

Erratum for Yang et al., "A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects"

Correction To: A Selective Review of Negative Control Methods in Epidemiology

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Corrigendum to “efficacy and Safety of Aripiprazole in Chinese Han Schizophrenia Subjects: A Randomized, Double-Blind, Active Parallel-Controlled, Multicenter Clinical Trial” [schizophr. Res. 157 (1–3) (august 2014) 112–119]

Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study

Corrigendum: Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review